KIR/CD158 Antibody (lirilumab) [DyLight 755]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28035IR
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
ELISA, Flow Cytometry, Functional
Label
DyLight 755 (Excitation = 754 nm, Emission = 776 nm)
Antibody Source
Recombinant Monoclonal Human IgG4 Clone # lirilumab
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for KIR/CD158 Antibody (lirilumab) [DyLight 755]
Immunogen
KIR
Clonality
Monoclonal
Host
Human
Isotype
IgG4
Applications for KIR/CD158 Antibody (lirilumab) [DyLight 755]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: KIR/CD158
Alternate Names
CD158
Gene Symbol
KIR2DL1
Additional KIR/CD158 Products
Product Documents for KIR/CD158 Antibody (lirilumab) [DyLight 755]
Product Specific Notices for KIR/CD158 Antibody (lirilumab) [DyLight 755]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...